Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

Phase 1

Completed

• Conditions: Parkinson's Disease; Constipation
• Interventions: Other: Placebo; Drug: ENT-01

• Registration Number: NCT03047629
• Lead Sponsor: Enterin Inc.

Brief Summary

This is a Phase 1/2a study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally-administered medication to relieve symptoms of constipation associated with Parkinson's Disease. Ten patients will be enrolled in Phase 1, and will be studied over an 8-12 week period. Forty patients will be enrolled in Phase 2, and will be studied over an 8-10 week period. All subjects will receive the study drug during one of the observational periods of the study.

Detailed Description

Phase 1 will enroll 10 patients to assess the safety, tolerability, and pharmacokinetics of single escalating doses over a 30-60 day period. The dose-escalation period will be preceded by a 2-week run in period and followed by a 2-week wash-out period.

Phase 2 follow the safe completion of Phase 1. It will enroll 40 patients and is composed of 4 periods of study: 1) a 2-week run-in period, 2) a 3-5 week escalating dose period to identify a prokinetic dose in the initial set of 10 patients, 3) a 1-week period of randomized dosing (placebo versus the previously identified pro-kinetic dose), and 4) a 2-week wash-out period. Pharmacodynamics will be assessed along with safety and tolerability. Relative outcomes will be compared within each patient and across groups for the randomized dosing period.

Frequency of bowel movements and other non-motor symptoms of Parkinson's Disease will be collected over the course of both phases.

Study Timeline

• Study First Submitted: 2017-02-03
• Study First Submitted QC: 2017-02-06
• Study First Posted: 2017-02-09
• Study Start: 2017-05-11
• Primary Completion: 2018-04-25
• Study Completion: 2018-06-14
• Results First Submitted: 2023-09-21
• Results First Submitted QC: 2023-11-07
• Results First Posted: 2023-11-30
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-04
• Last Update Posted: 2023-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Parkinson's disease diagnosis confirmed by a neurologist specializing in movement disorders

2. Insufficient criteria for a diagnosis of Irritable Bowel Syndrome

3. Constipation for over 6 months, unresponsive to Milk of Magnesia, and requiring at least weekly treatment using an oral laxative, stool softener, bulking agent, and/or a suppository, and dissatisfaction with current treatment.

4. Body Mass Index is 18-40 kg/m2

5. At least 2 of the Rome IV functional constipation criteria are met

6. Loose stools are rarely present without the use of laxatives

7. Patient is willing and able to sign informed consent and comply with all study procedures

8. Patients must be able to read, understand, and accurately record data into the diary to guarantee full participation in the study

   Females only:

9. Must have negative serum or urine pregnancy tests and must not be lactating

10. If of child-bearing age: Must agree to using a hormonal (i.e., oral, implantable, or injectable) and either single- or double-barrier method of birth control throughout the study period. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.

11. If unable to have children: Must have this documented in the case report form (i.e., ubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone in women less than 60 years of age.

Exclusion Criteria

1. Unable or unwilling to provide informed consent or to comply with study procedures
2. Diagnosis of secondary constipation beyond that of PD
3. Structural or metabolic diseases that affect the GI system
4. Functional GI disorder
5. Unable or unwilling to withdraw from taking the following medications 2 weeks prior to the dose-escalation period and throughout the study: Laxatives, opiates, sedatives, hypnotics, anti-histamines, protein pump inhibitors or any medications which may cause constipation
6. History of recent major surgery (within 60 days of screening)
7. Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator
8. Neurological disorder other than PD
9. On treatment with intra-jejunal dopamine
10. Treatment with COMT inhibitors for fewer than 4 weeks (entacapone, tolcapone, Stalevo)
11. Unable to maintain a stable diet regimen
12. Patients with a cognitive impairment that preclude them from understanding the informed consent
13. Patients placed under legal guardianship
14. Acute GI illness within 48 hours of the baseline period
15. History of major GI surgery (e.g. previous abdominal surgery, including cholecystectomy), except that patients with uncomplicated appendectomy are allowed
16. ALT or AST > 1.5 X upper limit of normal (ULN) during screening
17. Females who are pregnant or breastfeeding
18. History of excessive alcohol use or substance abuse
19. Patient or caregiver unable to administer daily oral dosing
20. Participation in an investigational clinical study within the 6 months prior to dosing in the present study
21. Any other reason, which in the opinion of the Investigator would confound proper interpretation of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Placebo Comparator	Placebo	Placebo to be taken by mouth every day upon awakening
ENT-01	ENT-01	ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events.	Through study completion, up to 11 weeks	Specific treatment related events of recurrent vomiting, recurrent diarrhea, abdominal pain, and hypotension will be assessed with respect to grade and frequency of occurrence.

Secondary Outcome Measures

Name	Time	Method
Frequency of Bowel Movements	Through study completion, up to 11 weeks	The frequency of spontaneous bowel movements will be assessed at each dose across the study population and compared to baseline measures.

Trial Locations

Locations (15)

Keck Hospital of University of Southern California; 🇺🇸 Los Angeles, California, United States

Rocky Mountain Movement Disorders Center, PC; 🇺🇸 Englewood, Colorado, United States

Georgetown Universtiy, Department of Neurology; 🇺🇸 Washington, District of Columbia, United States

Parkinson's Disease and Movement Disorders Center of Boca Raton; 🇺🇸 Boca Raton, Florida, United States

Neuroscience Research, University of Florida Jacksonville; 🇺🇸 Jacksonville, Florida, United States

MEDSOL Clinical Research; 🇺🇸 Port Charlotte, Florida, United States

Suncoast Neuroscience Associates, Inc; 🇺🇸 Saint Petersburg, Florida, United States

Sarasota Memory Hospital Clinical Research Ctr.; 🇺🇸 Sarasota, Florida, United States

USF Health Byrd Parkinson's Disease Movement Disorders Center of Excellence; 🇺🇸 Tampa, Florida, United States

Quest Research Institute; 🇺🇸 Farmington Hills, Michigan, United States

Scroll for more (5 remaining)